N,N-bis(2-oxo-3-oxazolidinyl)phosphoramidic chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: N,N-bis(2-oxo-3-oxazolidinyl)phosphoramidic chloride
• 英文别名: N,N-bis(2-oxo-3oxazolidinyl)phosphoramidic chloride；3-[dichlorophosphoryl-(2-oxo-1,3-oxazolidin-3-yl)amino]-1,3-oxazolidin-2-one
• 化学式: C₆H₈Cl₂N₃O₅P
• 分子量: 304.026
• InChiKey: NUEGMCDCRMDIBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  79.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-甲基炔丙基胺 、 N,N-bis(2-oxo-3-oxazolidinyl)phosphoramidic chloride 、 4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylbutanoic acid 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-N-methyl-2-phenyl-N-prop-2-ynyl-butyramide
  参考文献：
  名称：

  N-alkynyl carboxamides as sertonergic agents

  摘要：

  化合物##STR1##中：R和R.sup.6分别是从H，CN，OR.sup.2，NO.sub.2，NR.sup.2 R.sup.3，NR.sup.2 COR.sup.3，NR.sup.2 COOR.sup.3，COR.sup.2，COOR.sup.2，CONR.sup.2 R.sup.3，SR.sup.2，SOR.sup.2，SO.sub.2 R.sup.2，SO.sub.2 NR.sup.2 R.sup.3，烷基，烯基，炔基，全氟烷基和卤素组成的群体中独立选择的成员；其中R.sup.2和R.sup.3是烷基，烯基，炔基，苯基或苄基；R.sup.4是从H，烷基，杂原子烷基（其中杂原子是氧，硫或氮），烯基和炔基组成的群体中选择的成员；R.sup.5是含有2至8个碳原子的炔基或含有2至6个碳原子的炔基环烷基，其中环烷基含有3至10个碳原子；或其药用可接受盐，可用作抗焦虑/抗抑郁剂。

  公开号：

  US05451584A1
• 作为试剂：
  描述：

  3-(N-叔丁氧羰基-4-氨基苯基)丙酸 在 palladium on activated charcoal N,N-bis(2-oxo-3-oxazolidinyl)phosphoramidic chloride 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-[4-(2-hydroxycarbamoyl-ethyl)phenyl]-4-phenyl-butyramide
  参考文献：
  名称：

  Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors

  摘要：

  Previously, we developed a strategy to develop a novel class of histone deacetylase (HDAC) inhibitors by tethering short-chain fatty acids with Zn2+-chelating motifs, which led to N-hydroxy-4-(4-phenylbutyryl-amino)benzamide (HTPB), a hydroxamate-tethered phenylbutyrate derivative with sub-micromolar potency in inhibiting HDAC activity and cancer cell proliferation. In this study, we carried out structure-based optimization of HTPB by using the framework generated by the structure of histone deacetylase-like protein (HDLP)-trichostatin A (TSA) complexes. Docking of HTPB into the HDLP binding domain suggested that the hydrophobic microenvironment encompassed by Phe-198 and Phe-200 could be exploited for structural optimization. This premise was corroborated by the greater potency of (S)-(+)-N-hydroxy-4-(3-methyl-2-phenylbutyrylamino)-benzamide [(S)-11] (IC50 in HDAC inhibition, 16 nM), of which the isopropyl moiety was favorable in interacting with this hydrophobic motif. (S)-11 at concentrations as low as 0.1 mu M was effective in causing histone hyperacetylation and p21(WAF/CIP1) overexpression and suppressing proliferation in cancer cells.

  DOI：

  10.1021/jm0503749

文献信息

• N-heterocycloalkyl carboxamides as serotonergic agents
  申请人：American Home Products Corporation

  公开号：US05602128A1

  公开（公告）日：1997-02-11

  The compounds ##STR1## where R and R.sup.6 are members independently selected from the group consisting of H, CN, OR.sup.2, NO.sub.2, NR.sup.2 R.sup.3, NR.sup.2 COR.sup.3, NR.sup.2 COOR.sup.3, COR.sup.2, COOR.sup.2, CONR.sup.2 R.sup.3, SR.sup.2, SOR.sup.2, SO.sub.2 R.sup.2, SO.sub.2 NR.sup.2 R.sup.3, alkyl, alkenyl, alkynyl, perhaloalkyl, and a halogen; in which R.sup.2 and R.sup.3 are alkyl, alkenyl, alkynyl, phenyl, or benzyl; R.sup.4 is a member selected from the group consisting of H, alkyl, heteroalkyl, in which the hetero atom is oxygen, sulfur or nitrogen, alkenyl and alkynyl; R.sup.5 is ##STR2## where X is O, S or NR.sup.7 and R.sup.7 is H or alkyl and n is 1, 2, 3, 4, 5, or 6; or a pharmaceutically acceptable salt thereof, are useful anxiolytic/antidepressant agents.

  化合物##STR1##其中R和R.sup.6是独立选择自H，CN，OR.sup.2，NO.sub.2，NR.sup.2R.sup.3，NR.sup.2COR.sup.3，NR.sup.2COOR.sup.3，COR.sup.2，COOR.sup.2，CONR.sup.2R.sup.3，SR.sup.2，SOR.sup.2，SO.sub.2R.sup.2，SO.sub.2NR.sup.2R.sup.3，烷基，烯基，炔基，全卤烷基和卤素的一组中的成员;其中R.sup.2和R.sup.3是烷基，烯基，炔基，苯基或苄基;R.sup.4是从H，烷基，杂环烷基（其中杂原子是氧，硫或氮），烯基和炔基中选择的成员;R.sup.5是##STR2##其中X是O，S或NR.sup.7，R.sup.7是H或烷基，n为1，2，3，4，5或6;或其药学上可接受的盐，是有用的抗焦虑/抗抑郁剂。
• 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION
  申请人：Halperin Jose A.

  公开号：US20090299058A1

  公开（公告）日：2009-12-03

  Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.

  本发明提供了使用3-(5-叔丁基-2-羟基苯基)-3-苯基-1,3-二氢吲哚-2-酮及/或其衍生物来抑制翻译的组合物和方法。本发明还描述了使用3-(5-叔丁基-2-羟基苯基)-3-苯基-1,3-二氢吲哚-2-酮及/或其衍生物治疗(1)细胞增殖性疾病，(2)非增殖性退行性疾病，(3)病毒感染和/或(4)与病毒感染相关的疾病的组合物、方法和试剂盒。
• 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation
  申请人：Halperin José A.

  公开号：US20100249201A1

  公开（公告）日：2010-09-30

  Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.

  本发明提供了使用3-(5-叔丁基-2-羟基苯基)-3-苯基-1,3-二氢吲哚-2-酮及/或其衍生物来抑制翻译的组合物和方法。本发明还描述了使用3-(5-叔丁基-2-羟基苯基)-3-苯基-1,3-二氢吲哚-2-酮及/或其衍生物来治疗(1)细胞增殖性疾病、(2)非增殖性、退行性疾病、(3)病毒感染和/或(4)与病毒感染相关的疾病的组合物、方法和试剂盒。
• N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION
  申请人：Aktas Bertal Huseyin

  公开号：US20120115915A1

  公开（公告）日：2012-05-10

  Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

  本文提供了抑制翻译起始的组合物和方法。描述了使用N，N'-二芳基脲和/或N，N'-二芳基硫脲化合物治疗（1）细胞增生性疾病，（2）非增生性退行性疾病，（3）病毒感染和/或（4）与病毒感染相关的疾病的组合物、方法和试剂盒。
• Compounds for the Inhibition of Cellular Proliferation
  申请人：Chorev Michael

  公开号：US20130178505A1

  公开（公告）日：2013-07-11

  Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.

  提供了抑制翻译的组合物和方法。本文披露的化合物可用于治疗以下疾病：（1）细胞增殖性疾病，（2）非增殖性退行性疾病，（3）病毒感染，（4）与病毒感染有关的疾病，以及（5）非增殖性代谢性疾病，如II型糖尿病，其中抑制翻译起始有益。本文还提供了用于治疗上述疾病的方法和试剂盒。